I-Mab Starts Clinical Development of Two 4-1BB Bispecific Candidates

Shanghai I-Mab announced it has achieved several clinical milestones in its portfolio of 4-1BB bispecific antibodies. I-Mab's lead bi-specific antibody assets are undergoing clinical development in the US . The first patient was dosed in a US Phase I clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors. China  sites will join the dose expansion part of the trial. Results from TJ-L14B/ABL503 preclinical studies showed improved anti-tumor activity over 4-1BB and PD-L1 mAbs as single agents alone or in combination. More details.... Stock Symbol: (NSDQ: IMAB)  Share this with colleagues: // //